Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of BioForm Medical, Inc. (Nasdaq: BFRM) arising from the Company’s announcement of its intent to be acquired by Merz Pharma Group.

On January 4, 2010, BioForm announced its plan to merge with Merz. Under the terms of the merger agreement, BioForm shareholders will receive $5.45 in cash for every share of BioForm stock they own in a transaction valued at $253 million.

The investigation is focused on the potential unfairness of the consideration to be paid to BioForm shareholders as well as the potential unfairness of the process by which the BioForm Board of Directors is addressing the transaction.

If you are interested in discussing your rights as a BioForm shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it